Lyrica
Product Images NDC 43353-840

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 43353-840). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50mg (43353 263)

Label for Lyrica (Pregabalin) capsules, 50 mg strength, containing 60 capsules. The label includes a warning that the drug may be habit forming and provides storage instructions. It specifies the manufacturer as Pfizer Asia Pacific Pte. Ltd., Singapore, with repackaging by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. The product is marked RX Only.*

FDA Label Image

Bottle Label 75mg (43353 264)

Label for Pregabalin (Lyrica) 75 mg capsules, containing 60 capsules. The label includes storing instructions, a warning that the drug may be habit forming, and manufacturing details by Pfizer Asia Pacific Pte. Ltd., Singapore. Repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Marked as prescription only (RX Only).*

FDA Label Image

Bottle Label 100mg (43353 413)

Label for Pregabalin (Lyrica) capsules 100 mg, containing 120 capsules. The label includes a warning about habit forming, storage instructions between 20-25 degrees Celsius, and mentions that the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC, sourced from Pfizer Pharmaceuticals LLC.*

FDA Label Image

Bottle Label 150mg (43353 414)

Lyrica (Pregabalin) 150 mg capsules label for a 120-capsule bottle. The label includes drug name, strength, quantity, and a warning that the medication may be habit forming. It identifies the manufacturer as Pfizer Pharmaceuticals LLC, repackaged by Aphena Pharma Solutions - Tennessee, LLC. The label also notes the prescription status (Rx Only) and contains NDC numbers and barcodes.*

FDA Label Image

Bottle Label 200mg (43353 675)

Label of Pregabalin (Lyrica) 200 mg capsules showing a package of 60 capsules. The label includes a warning about habit-forming potential and storage instructions. Manufactured by Pfizer Asia Pacific Pte Ltd, Singapore, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN.*

FDA Label Image

Bottle Label 300mg (43353 840)

Label for Pregabalin (Lyrica) 300 mg, 60 capsules, produced by Aphena Pharma Solutions - Tennessee, LLC. The label includes a habit-forming warning, storage instructions, manufacturing and repackaging details, and states RX only. Barcodes and batch information are also visible.*

FDA Label Image

Bottle Label 225mg (43353 876)

Label for Pregabalin (Lyrica) capsules, 225 mg strength, containing 60 capsules. Label includes warning that the medication may be habit-forming. Manufactured by Pfizer Asia Pacific Pte. Ltd., Singapore, and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. The label also states prescription use only (Rx Only) and includes batch and lot numbers.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure (Lyrica 01)

A formula calculating estimated creatinine clearance (CLCr) based on age, weight, and serum creatinine levels, with a multiplication factor for female patients. The formula is part of dosing or clinical guidance text.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of Lyrica's active ingredient, showing its molecular components including an amino group (NH2) and a carboxylic acid group (CO2H).*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline for various Pregabalin doses (200 mg, 100 mg, 25 mg three times a day) and placebo. The graph compares effectiveness across different Pregabalin doses and placebo for pain improvement.*

FDA Label Image

Figure 2 (Lyrica 04)

A line graph showing the percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. Two lines compare Pregabalin 100 mg three times a day and placebo, indicating patient improvement in pain reduction over a range of values.*

FDA Label Image

Figure 3 (Lyrica 05)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, against a placebo, showing trends in pain improvement across these groups.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph comparing percent improvement in pain from baseline with percent of patients improved for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The X-axis shows percent improvement in pain, and the Y-axis shows percent of patients improved.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing trends in pain improvement over a range of percentages.*

FDA Label Image

Figure 6 (Lyrica 08)

Bar graph showing responder rates (%) for various dosages of Lyrica compared to placebo in two separate studies labeled Study E1 and Study E3. Each study compares placebo with daily doses of 50 mg, 150 mg, 300 mg, and 600 mg, displaying increased responder rates with higher doses.*

FDA Label Image

Figure 7 (Lyrica 09)

A line graph depicting seizure reduction as median percent change from baseline across increasing doses (mg/day) for four studies labeled E1BD, E2TD, E3BD, and E3TD. The graph shows significant seizure reduction (p ≤ 0.0001) with increasing dose, with separate markers for each study type.*

FDA Label Image

Figure 8 (Lyrica 10)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares four groups: Pregabalin 600mg daily dose, 450mg daily dose, 300mg daily dose, and placebo, illustrating varying levels of pain improvement over a percent scale.*

FDA Label Image

Figure 9 (Lyrica 11)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR over 180 days. The graph compares two groups: Pregabalin (solid line) and Placebo (dashed line), showing a higher percentage without LTR in the Pregabalin group throughout the study period.*

FDA Label Image

Figure 10 (Lyrica 12)

A line graph depicting the percent of subjects improved over time from baseline to week 12 based on BOCF. The graph compares two groups: Pregabalin and Placebo, showing a higher percent improvement for Pregabalin across the x-axis percentage range.*

FDA Label Image

Figure 11 (Lyrica 13)

A survival curve chart comparing the percent of subjects improved over time from baseline to week 16 for two groups: Pregabalin and Placebo. The X-axis represents percent improved from baseline to week 16 BOCF, and the Y-axis shows the percent of subjects improved, ranging from 0 to 100 percent. The Pregabalin group shows higher percent improvement over time than the Placebo group.*

FDA Label Image

Logo (Lyrica 14)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.